Imricor Medical Systems, Inc. · ASX:IMR
Imricor Medical Systems — NWR Virtual Conference – Series 11 (May 2022)
21 slides from Imricor Medical Systems's conference presentation, May 2, 2022
Slide 1: Investor Presentation – NWR Virtual Conference Series 11
For personal use only Investor Presentation NWR Virtual Conference – Series 11 May 2022 IMRICOR MEDICAL SYSTEMS, INC (ASX:IMR) WWW.IMRICOR.COM
Slide 2: Disclaimer
Disclaimer For personal use only The material contained in this presentation is intended to be general background those which we expect, depending on the outcome of various factors. Investors and others information on Imricor Medical Systems, Inc. (Imricor) and its activities. are cautioned not to p
Slide 3: Introduction to Imricor
For personal use only Introduction to Imricor
Slide 4: Transitioning cardiac ablation into a new kind of lab
Transitioning cardiac ablation into a new kind of lab Conventional x-ray EP lab iCMR EP lab (interventional cardiac magnetic resonance) For personal use only X-ray to iCMR Everyone else Only Imricor INVESTOR PRESENTATION | 4
Slide 5: Transitioning cardiac ablation into a new kind of lab
Transitioning cardiac ablation into a new kind of lab Conventional x-ray EP lab iCMR EP lab (interventional cardiac magnetic resonance) For personal use only X-ray to iCMR Everyone else Only Imricor Physicians, Patients, Hospitals Imricor Annual consumable device revenue per iCMR • Advantages of MRI
Slide 6: Imricor at a glance
Imricor at a glance For personal use only Imricor develops commercially viable and safe MRI-compatible products to the cardiac catheter ablation market $6bn addressable 2 core 15 labs Regulatory approval market1 products signed in EU and NZ with favourable • Advantage-MR EP to date across Germany, a
Slide 7: Investment Highlights
Investment Highlights For personal use only Founder-led business with The world’s first and only deep med-tech experienced commercially available MRI management team compatible ablation catheter Large addressable market, Strong IP portfolio estimated to be $6bn1 in and patent protection What are the
Slide 8: Company timeline
Company timeline For personal use only 2019 Listed on ASX (ASX: IMR) 2006 Imricor is established 2020 Received CE mark approval for Vision-MR Ablation Cather & 2007 Licensed IP from Johns Vision-MR Dispersive Electrode Hopkins University Signed collaborative sales distribution agreement with Philips
Slide 9: A strong and growing market in cardiac ablation
A strong and growing market in cardiac ablation For personal use only Drivers of Global Catheter Cardiac Ablation Disposables Market: Ablation Market US, EU, ANZ CATHETER SALES (USD M) $9,000.00 Increased incidence of cardiac disease $8,000.00 R $7,000.00 . 2 % CAG 8 $6,000.00 Shift towards $5,000.0
Slide 10: Problems solved through iCMR ablation procedures
Problems solved through iCMR ablation procedures For personal use only Visualisation Procedure effectiveness Cost Procedure time Safety • X-ray imaging provides • Inability to determine • Repeat procedures can • Conventional 3D • Patient and doctor poor heart visualisation permanency of lesions resu
Slide 11: Current product portfolio – enabling ablations guided by iCMR
Current product portfolio – enabling ablations guided by iCMR Consumable Products For personal use only Vision-MR Ablation Catheter Vision-MR Dispersive Electrode • Received CE mark approval in January 2020 • Ablation catheter CE mark approval with an indication for treating type 1 atrial flutter •
Slide 12: Support from Key Opinion Leaders
Support from Key Opinion Leaders For personal use only “Today we did our first case “Today in our ablation we “We are very excited to “It is obvious to us that iCMR since COVID. It was a realised that we were have taken this important guided ablation will be part of beautiful case, and it’s limited
Slide 13: A strong intellectual property portfolio
A strong intellectual property portfolio For personal use only Imricor’s IP is relatively new, with the Company’s oldest issued patent expiring in 2030 19 issued U.S Patents In addition to protecting Imricor’s devices and procedures, its patents provide an opportunity for the Company to license its
Slide 14: Imricor business model
Imricor business model For personal use only REVENUE MODEL Today Imricor Capital Equipment Consumables primarily generates (One-off sale) (Ongoing sales) Other revenue from the sale of its capital equipment and consumable products Advantage-MR EP Vision-MR Ablation IP Licensing Recorder/Stimulator C
Slide 15: Imricor has multiple drivers of growth
Imricor has multiple drivers of growth How Imricor grows in short-term How Imricor grows in mid-term For personal use only Key drivers to growing the number of iCMR sites include: Key drivers to increasing the number of iCMR ablation procedures doctors can perform include: • Existing iCMR sites comm
Slide 16: Path to significant scale
Path to significant scale For personal use only 2022 End of 2023 2024 2025-2026 Current business value Growing business value Expanding business value Continued growth – iCMR proposition – iCMR Atrial proposition – iCMR Ventricular proposition – FDA approval Atrial Fibrillation Ablations Flutter Abl
Slide 17: Compelling Value Propositions
Compelling Value Propositions Imricor believes its products have the potential to successfully address unmet needs in For personal use only the cardiac catheter ablation market and deliver value to stakeholders Patient Doctor Payer Hospital ü Higher single procedure ü Improved visualisation of ü Sim
Slide 18: Business Update and Outlook
For personal use only Business Update and Outlook
Slide 19: Our focus for the year ahead
Our focus for the year ahead Focused on managing the recovery from the effects of the COVID-19 pandemic For personal use only 1 2 3 Commercialisation Growth Initiatives Products • Steady re-launch of site • Advance strategy around • Consumable devices for expansion in 2022 clinical trials that expan
Slide 20: Contact Information
Contact Information For personal use only Investors & Australian Media: Simon Hinsley NWR Communications simon@nwrcommunications.com.au +61 401 809 653 Investors: Steve Wedan Executive Chair, President & CEO Email: steve.wedan@imricor.com Rest of World Media: Nick Twohy Director of Marketing, Imrico
Slide 21: Strong management team with deep MedTech experience
Strong management team with deep MedTech experience For personal use only Steve Wedan, Lori Milbrandt, Gregg Stenzel, Jon Gut, CEO CFO COO incoming CFO • Over 30 years of medical device • Over 35 years of accounting and • Over 25 years of medical device • Over 13 years of accounting and experience,
Imricor Medical Systems — NWR Virtual Conference – Series 11 (May 2022) on 6ix